Legend Biotech Corporation (NASDAQ:LEGN) is a top healthcare stock with a high upside potential. Analysts like J.P. Morgan’s Jessica Fye and TD Cowen’s Yaron Werber have set bullish price targets of $76 and $62, respectively. Despite current supply constraints, the company aims to hit $1.9 billion in sales by 2025.

Legend Biotech Corporation is a clinical-stage company focused on oncology therapies. While the company faces challenges, it plans to overcome them with strategic expansions. Analysts are optimistic about its growth potential and strategic positioning, making it an attractive investment opportunity.

Investors see potential in LEGN, but some believe there are better opportunities in AI stocks. For those seeking undervalued AI stocks with significant growth potential, consider exploring other options. The company’s confidence in meeting sales targets by 2025 reflects its determination to succeed despite current obstacles.

Read more at Yahoo Finance: J.P. Morgan Maintains a Buy on Legend Biotech Corporation (LEGN)